Advertisement

Topics

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

20:00 EDT 25 Jul 2017 | Allergy Asthma and Clinical Immunology

Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician’s global evaluation of treatment effectiveness (GETE). A good clinical and...

Original Article: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

NEXT ARTICLE

More From BioPortfolio on "4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry"

Advertisement
Quick Search
Advertisement
Advertisement